All IndicationsPhase 3Phase 2Phase 2Phase 2Phase 2
Chronic Kidney Disease
6
Companies
6
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
DVAX
Dynavax Technologies Corporation
HEPLISAV-B
JNJ
Johnson & Johnson
epoetin alfa
SNY
Sanofi
Sevelamer hydrochloride
HSCSW
HeartSciences Inc.
Sodium Bicarbonate
4151.T
Kyowa Kirin Co., Ltd.
RTA 402
DHCNL
Delos Healthy Communities
lorundrostat
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| DVAX Dynavax Technologies Corporation | HEPLISAV-B | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | epoetin alfa | Phase 2 | — | — | — |
| SNY Sanofi | Sevelamer hydrochloride | Phase 2 | — | — | — |
| HSCSW HeartSciences Inc. | Sodium Bicarbonate | Phase 2 | — | — | — |
| 4151.T Kyowa Kirin Co., Ltd. | RTA 402 | Phase 2 | — | — | — |
| DHCNL Delos Healthy Communities | lorundrostat | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
1
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.